Overview

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The safety and efficacy of basal insulin during intravenous insulin infusion for hyperglycemic crisis patients under critical care is still unknown. We assumed that concurrent basal insulin subcutaneous injection and intravenous insulin infusion for critically ill DKA and HHS patients would shorten the time of hyperglycemic crisis correction and achieved better glycemic control(decrease hypoglycemia and rebound hyperglycemia).

Phase:

Phase 2

Details

Lead Sponsor:

Changhua Christian Hospital

Treatments:

Insulin Glargine